魏粉菊, 马悦, 俞霁, 贾海永, 刘新泳, 展鹏. 基于新靶标的HBV抑制剂研究进展(2):RNase H及其他靶标J. 药学学报, 2020,55(4): 566-574. doi: 10.16438/j.0513-4870.2019-0711
引用本文: 魏粉菊, 马悦, 俞霁, 贾海永, 刘新泳, 展鹏. 基于新靶标的HBV抑制剂研究进展(2):RNase H及其他靶标J. 药学学报, 2020,55(4): 566-574. doi: 10.16438/j.0513-4870.2019-0711
WEI Fen-ju, MA Yue, YU Ji, JIA Hai-yong, LIU Xin-yong, ZHAN Peng. Advances in research on HBV inhibitors based on new targets (2): RNase H and othersJ. Acta Pharmaceutica Sinica, 2020,55(4): 566-574. doi: 10.16438/j.0513-4870.2019-0711
Citation: WEI Fen-ju, MA Yue, YU Ji, JIA Hai-yong, LIU Xin-yong, ZHAN Peng. Advances in research on HBV inhibitors based on new targets (2): RNase H and othersJ. Acta Pharmaceutica Sinica, 2020,55(4): 566-574. doi: 10.16438/j.0513-4870.2019-0711

基于新靶标的HBV抑制剂研究进展(2):RNase H及其他靶标

Advances in research on HBV inhibitors based on new targets (2): RNase H and others

  • 摘要: 乙型肝炎已成为影响我国人民身体健康和社会发展的重大疾病之一。乙肝发病率高,病程长,目前已上市的抗乙肝病毒小分子药物无法治愈乙肝,因此,研发安全高效的新型乙肝病毒抑制剂具有重要意义。本综述承接前文关于HBV衣壳蛋白抑制剂的研究进展,精选近几年具有代表性的研究实例,从药物化学的视角总结了抗乙肝病毒药物RNase H类及其他靶标抑制剂的前沿进展。

     

    Abstract: Hepatitis B has become one of the major diseases which seriously affect people's health and social development. Hepatitis B, with high incidence and long disease course, cannot be cured by approved drugs such as the nucleoside analogues. Therefore, the discovery of safe and efficient novel HBV inhibitors is of great significance. From the point of view of medicinal chemistry, we summarized and discussed current endeavours towards the discovery and development of anti-HBV agents of RNase H and other novel target inhibitors with various scaffolds or distinct mechanisms of action, besides the existing capsid protein inhibitors.

     

/

返回文章
返回